Pramlintide

This classification denotes an anti-diabetic agent with the molecular formula C171H267N51O53S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D3FM8FA78T, chemically known as l-tyrosinamide, l-lysyl-l-cysteinyl-l-asparaginyl-l-threonyl-l-alanyl-l-threonyl-l-cysteinyl-l-alanyl-l-threonyl-l-glutaminyl-l-arginyl-l-leucyl-l-alanyl-l-asparaginyl-l-phenylalanyl-l-leucyl-l-valyl-l-histidyl-l-seryl-l-seryl-l-asparaginyl-l-asparaginyl-l-phenylalanylglycyl-l-prolyl-l-isoleucyl-l-leucyl-l-prolyl-l-prolyl-l-threonyl-l-asparaginyl-l-valylglycyl-l-seryl-l-asparaginyl-l-threonyl-, cyclic (2-7)-disulfide but more generally known as pramlintide, which bears US NIH Compound Identifier 16132446. European Medicines Agency schedules Pramlintide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09993MIG. The term PRAMLINTIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 10, No. 3, 1996, List 36) WHO schedules pramlintide in its Anatomical Therapeutic Chemical (ATC) Classification. PRAMLINTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule pramlintide under HS 29349990 and SITC 51579. As of Q4 2014, PRAMLINTIDE remains US FDA's Preferred Term for this commodity. Pramlintide bears US NLM identifiers UMLS ID C0537551 and NCI Concept Code C61901. SMILES: SCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CCCCN)CS)CC(=O)N)C(O)C)C)C(O)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1C(CCC1)C(=.